Vertical Pharmaceuticals, LLC
Vertical Pharmaceuticals, LLC, an Osmotica Company
Vertical Pharmaceuticals LLC is a division of Osmotica Pharmaceuticals plc, a fully-integrated biopharmaceutical company with corporate offices in Bridgewater, New Jersey focused on developing, manufacturing and commercializing specialty products. Our diversified product portfolio, forms the foundation of our unwavering commitment to improving patients' lives, while our late-stage pipeline is highlighted by two NDA candidates that recently completed Phase III clinical trials: arbaclofen extended‑release tablets for spasticity in multiple sclerosis patients and RVL‑1201 (oxymetazoline hydrochloride ophthalmic solution, 0.1%) for the treatment of blepharoptosis, or droopy eyelid. RVL-1201 represents our entry into eye care, and a meaningful advance in the treatment paradigm for eye-care professionals and patients alike.
Line 1 Acquired Blepharoptosis